Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427908 | 0.91 | TYMP (0.44) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL12427963 | 0.84 | TYMP (0.43) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL12427918 | 0.82 | TYMP (0.43) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL943184 | 0.81 | TYMP (0.43) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL941529 | 0.81 | LMNA (0.46) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL12427881 | 0.81 | TYMP (0.43) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL12427903 | 0.81 | TYMP (0.46) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL12427873 | 0.77 | KMT2A (0.46) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL942325 | 0.77 | KMT2A (0.46) | TYMPKMT2ACA12CA1CA2 | |
| SCHEMBL14043089 | 0.77 | KMT2A (0.44) | TYMPKMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | TYMP 797/4885KMT2A 610/4885CA12 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.